Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors

NCT04471415 is registered in ClinicalTrials.gov with Dracen Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04471415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid Tumors
Lead sponsor
Dracen Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2020
Completion date
March 28, 2023
Enrollment
61 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, non small cell lung cancer metastatic